


### Sampling Experiment



### Survival Experiment

Figure S1

**Supplementary Table S1 Primers used for RT-PCR to detect mRNA**

	Sequence (5' → 3')	Direction	Length (bp)
CXCL-1	GCCAAGCCACAGGGGCGCCCGT	Forward	231
	ACTTGGGGACACCCTTTAGCATC	Reverse	
TNF- $\alpha$	TCCCAACAAGGAGGAGAAGTTCC	Forward	275
	GGCAGCCTTGTCCTTGAAGAGA	Reverse	
IL-10	GCAGGACTTTAAGGGTTACTTGG	Forward	245
	CCTTTGTCTTGGAGCTTATTAAA	Reverse	
MCL1	CTGGGGCAGGATTGTGACTC	Forward	169
	CACAAACCCATCCCAGCCTCTTTG	Reverse	
HGF	GCTACACTGGATTGATCAACGC	Forward	169
	CCATAATCTCCCTCACAAGGTC	Reverse	
iNOS	CCAACCTGCAGGTCTTCGATG	Forward	257
	GTCGATGCACAACCTGGGTGAAC	Reverse	
eNOS	CAGCCCTAAGACCTATGTGCAAG	Forward	219
	TAGCGTTGCTGATCCCGCAGCA	Reverse	
EF	TCTGGTTGGAATGGTGACAACATGC	Forward	335
	CCAGGAAGAGCTTCACTCAAAGCTT	Reverse	

*RT-PCR* reverse transcription-polymerase chain reaction, *bp* base pairs, *EF* elongation factor 1 $\alpha$

**Supplementary Table S2 Histological index in the liver of the HIRI+PH-treated rats**

		<i>P</i> value HIRI+PH vs HIRI+PH and ECLM
Average ± SD		
<i>Suzuki score</i>		
3 h		
HIRI+PH	4.0 ± 0.0	1.000
HIRI+PH and ECLM	5.3 ± 3.8	
6 h		
HIRI+PH	8.0 ± 2.6	0.010*
HIRI+PH and ECLM	1.8 ± 0.4	
24 h		
HIRI+PH	3.2 ± 0.7	0.879
HIRI+PH and ECLM	4.8 ± 2.9	
<i>TUNEL-positive cells/mm<sup>2</sup></i>		
6 h		
HIRI+PH	145.9 ± 45.9	0.004**
HIRI+PH and ECLM	22.3 ± 14.0	
<i>MPO-positive cells/mm<sup>2</sup></i>		
6 h		
HIRI+PH	79.2 ± 29.5	0.020*
HIRI+PH and ECLM	22.3 ± 11.2	
<i>Ki-67-positive nuclei (%)</i>		
24 h		
HIRI+PH	1.9 ± 0.6	0.007**
HIRI+PH and ECLM	4.3 ± 1.1	

\* *p* < 0.05 and \*\* *p* < 0.01 versus HIRI+PH alone.